Women are more likely to have PTSD than men, and women also experience depression more often, with one in seven women suffering from postpartum depression alone. Studies suggesting good results from just a few doses of MDMA or psilocybin combined with therapy have led the FDA to designate those drugs as breakthrough therapies for PTSD and treatment-­resistant depression, respectively. Is this the beginning of a brighter future for women’s health, one where common mental disorders, symptoms of chronic pain, and intense mood swings are managed with mind-altering trips? Hear from four psychedelic researchers leading the charge on research and advocacy and with unique insights into the opportunity and challenges ahead related to psychedelics for women’s health.